Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14064603 | 0.90 | L3MBTL1 (0.39) | L3MBTL1MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL12776772 | 0.89 | L3MBTL1 (0.35) | L3MBTL1ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1169867 | 0.88 | L3MBTL1 (0.38) | L3MBTL1MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL2079661 | 0.88 | GAA (0.36) | L3MBTL1ALDH1A1 | |
| SCHEMBL1169753 | 0.87 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1 | |
| SCHEMBL12844616 | 0.87 | MAPT (0.32) | MAPT | |
| SCHEMBL2080105 | 0.86 | MAPT (0.34) | L3MBTL1MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL2077750 | 0.79 | TSHR (0.38) | MAPTALDH1A1 | |
| SCHEMBL2079105 | 0.77 | CYP3A4 (0.33) | ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4823083 | 0.76 | L3MBTL1 (0.35) | L3MBTL1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897593-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897593-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| WO-2007143446-A1 | SPIRO-CONDENSED HETEROTRICYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070281917-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-06 | — | — | US | disclosed |
| US-20070281917-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-06 | — | — | US | disclosed |
| US-20070281917-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281917-A1 | HIV Integrase Inhibitors | TYMP, POLN, IMPDH1 | L3MBTL1 2696/4885MAPT 3231/4885ALDH1A1 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.